Whitehawk Therapeutics Inc (WHWK)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically...

Form S-3 - Registration statement under Securities Act of 1933

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference PR Newswire...

Form 8-K - Current report

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload PR...

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit PR Newswire...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities